L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:119949 CAPLUS Full-text
DN 140:267029
TI Miniaturization of Cell-Based β-Lactamase-Dependent FRET Assays to Ultra-High Throughput Formats to Identify Agonists of Human Liver X Receptors
AU Chin, Jayne; Adams, Alan D.; Bouffard, Aileen; Green, Ahren; Lacson, Raul G.; Smith, Todd; Fischer, Paul A.; Menke, John G.; Sparrow, Carl P.; Mitnaul, Lyndon J.
CS Department of Atherosclerosis and Endocrinology, Merck Research Laboratories, Rahway, NJ, USA
SO Assay and Drug Development Technologies (2003), 1(6), 777-787
CODEN: ADDTAR; ISSN: 1540-658X
PB Mary Ann Liebert, Inc.
DT Journal
LA English
AB Activation of liver X receptors (LXRs) induces reverse cholesterol transport and increases high-d. lipoprotein cholesterol in vivo. Here, we describe novel, functional, homogeneous cell-based fluorescence resonance energy transfer assays for identifying agonists of LXRs using β-lactamase as the reporter gene. Stable Chinese hamster ovary cell lines expressing LXRα-GAL4 or LXRβ-GAL4 fusion proteins that regulate β-lactamase transcription from upstream 7 + UAS GAL4 DNA binding sequences were generated and characterized. Synthetic and natural ligands of LXR dose-dependently activated the expression of β-lactamase in a subtype-specific manner. These assays were used to demonstrate that a 1-pyridyl hydantoin small mol. LXR synthetic ligand specifically activates LXRα receptors. The β-lactamase assays were optimized for cell d., DMSO sensitivity, and time of agonist stimulation. Clonal LXRβ-GAL4-β-lactamase cells were miniaturized into an ultra high throughput (3,456-well nanoplates) screening format.
IT **652992-38-6**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(FRET assays were used to demonstrate that a 1-pyridyl hydantoin small mol. LXR synthetic ligand specifically activates LXRα receptors.)
RN 652992-38-6 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:101150 CAPLUS Full-text
DN 140:146124
TI Preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions
IN Jones, A. Brian; Adams, Alan D.; Green, Ahren I.; Huang, Shaei Y.; Tse, Bruno; Gutteridge, Clare E.; Cheng, Yuan
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004011448	A1	20040205	WO 2003-US22807	20030721
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1534696	A1	20050601	EP 2003-771693	20030721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005239769	A1	20051027	US 2005-522114	20050124
PRAI	US 2002-398716P	P	20020725		
	WO 2003-US22807	W	20030721		

OS MARPAT 140:146124
GI



I



II

AB The present invention relates to novel benzisoxazoles (shown as I; variables defined below; e.g. II) as LXR (nuclear oxysterol receptor) ligands and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed

levels of HDL cholesterol. Although the methods of preparation are not claimed, .apprx.60 example prepns. of I and intermediates are included. For example, II was prepared from pyrrolidine-2,5-dione and 7-propyl-3-neopentyl-6-(3-bromopropyloxy)-1,2-benzisoxazole in DMF in the presence of Cs2CO3 at room temperature; 7-propyl-3-neopentyl-6-(3- bromopropyloxy)-1,2-benzisoxazole was prepared from 6-hydroxy-7-propyl-3- neopentyl-1,2-benzisoxazole, 1,3-dibromopropane and Cs2CO3 in DMF. The tested I have an IC50 ≤2 μM for at least one of either the LXRα or LXRβ receptors employing the LXR radioligand competition scintillation proximity assays described. Examples of I tested for LXR transactivation have an EC50 of <5,500 nM for at least one of LXRα or LXRβ receptor. Two examples of I were tested for their ability to increase cholesterol efflux from cultured human cells and the results are tabulated. For I: R1 = CF3, CH2CMe3, Ph, C1-6 alkyl, and C1-2-alkylphenyl; R2 = C1-6 alkyl, COOR3, CR3R4OR5, CR3R4SR5, and COR3; R3, R4 and R5 = H, Ph, and C1-6 alkyl; Y is joined together with the N and the carbonyl C shown in I to which Y is resp. attached, to form a heterocyclic ring = 5-membered rings (2-oxopyrrolidin-1-yl, 2-oxoimidazolidin-1-yl, 4-oxoimidazolidin-1-yl, 2-oxothiazolidin-3-yl, 4-oxothiazolidin-1-yl), 6-membered rings (2-oxopiperidin-1-yl, 3-oxomorpholin-4-yl, 2-oxohexahydropyrimidin-1-yl, 6-oxo-1,2,3,6-tetrahydropyrimidin-1-yl, 2-oxohexahydropyrimidin-1-yl, 2-oxo-1,2,3,6-tetrahydropyrimidin-1-yl, 2-oxopiperazin-1-yl, 2-oxohexahydrotriazin-1-yl, 2-oxoazepan-1-yl), bicyclic heterocycles (phthalimido and related imides); Z = -C1-6alkyl-, -C1-6alkyl-O-, -C3-6cycloalkyl-, and -C3-6cycloalkyl-O-.

IT **652992-50-2P**, 5-Methyl-5-(2-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate, chromatog. resolution; preparation of benzisoxazoles as LXR
ligands for treating dyslipidemic conditions)

RN 652992-50-2 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



546/272.1

514/338

IT **652992-51-3P**, (S)-5-Methyl-5-(2-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)

RN 652992-51-3 CAPLUS

CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(2-pyridinyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **652992-59-1P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-2-one **652992-60-4P**, Methyl 2-[2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]propanoate **652992-82-0P**, 6-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652992-83-1P**, 5-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)

RN 652992-59-1 CAPLUS

CN 2-Imidazolidinone, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-60-4 CAPLUS

CN 1-Imidazolidineacetic acid, α-methyl-2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 652992-82-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-6-phenyl-3-[3-[[7-propyl-3-

(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-83-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



IT **652992-23-9P**, 1-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-24-0P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-25-1P**, 2-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1H-isoindole-1,3(2H)-dione **652992-26-2P**, 3,3-Dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-27-3P**, 3-Methyl-3-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]pyrrolidine-2,5-dione **652992-28-4P**, 3-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]thiazolidine-2,4-dione **652992-29-5P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]thiazolidine-2,4-dione **652992-30-8P**, 5,5-Dimethyl-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]thiazolidine-2,4-dione **652992-31-9P**, [2,4-Dioxo-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1,3-thiazolidin-5-yl]acetic acid **652992-33-1P**, 3-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-34-2P**, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-35-3P**, 1-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-36-4P**, 5-(R)-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-37-5P**, 5,5-Dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-38-6P**, 1-(2-Pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-41-1P**, 5-Methyl-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-

yl]oxy]propyl]imidazolidine-2,4-dione **652992-42-2P**,
5-Methyl-5-phenyl-3-[3-[[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-
yl]oxy]propyl]imidazolidine-2,4-dione **652992-43-3P**,
5-Methyl-5-phenyl-3-[3-[[7-propyl-3-phenyl-1,2-benzisoxazol-6-
yl]oxy]propyl]imidazolidine-2,4-dione **652992-44-4P**,
5-Methyl-5-phenyl-3-[4-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-
yl]oxy]butyl]imidazolidine-2,4-dione **652992-45-5P**,
5-Methyl-5-(3-carboxyphenyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-48-8P**
, 5-Methyl-5-(4-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-49-9P**
, 5-Methyl-5-(3-pyridyl)-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-52-4P**
, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-
(pyrimidin-2-yl)imidazolidine-2,4-dione **652992-53-5P**,
3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-
(pyrazin-2-yl)imidazolidine-2,4-dione **652992-54-6P**,
3-[2,5-Dioxo-4-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-
6-yl]oxy]propyl]imidazolidin-4-yl]propanoic acid **652992-55-7P**,
4-[5,5-Dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]butanoic acid
652992-58-0P, 5-[5,5-Dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-
yl]pentanoic acid **652992-61-5P**, 2-[2-Oxo-3-[3-[[7-propyl-3-
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-
yl]propanoic acid **652992-62-6P**, 1-[3-[[7-Propyl-3-
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione
652992-65-9P, 5,5-Dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione **652992-70-6P**
, 1-[[trans-2-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-
yl]oxy]cyclohexyl]methyl]dihydropyrimidine-2,6(1H,3H)-dione
652992-72-8P, 1-[[trans-2-[[7-Propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]cyclopentyl]methyl]dihydropyrimidine-2,6(1H,3H)-
dione **652992-78-4P**, 1-[4-[7-Propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]butyl]dihydropyrimidine-2,6(1H,3H)-dione
652992-80-8P, 5-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione
652992-85-3P, 1,5-Dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione
652992-92-2P, 1-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione
652992-96-6P, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-
6-yl]oxy]propyl]-1-pyridin-2-yldihydropyrimidine-2,4(1H,3H)-dione
652993-00-5P, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-
6-yl]oxy]propyl]-5,6-dihydro-2H-1,2'-bipyrimidine-2,4(3H)-dione
652993-04-9P, 3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-
6-yl]oxy]propyl]-5,6-dihydro-2H-1,5'-bipyrimidine-2,4(3H)-dione
652993-06-1P, 1-[3-[[7-Propyl-3-(neopentyl)-1,2-benzisoxazol-6-
yl]oxy]propyl]piperidin-2-one **652993-08-3P**, 1-[3-[[7-Propyl-3-
(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2-one
652993-10-7P, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-
6-yl]oxy]propyl]piperidin-2,6-dione **652993-13-0P**,
1-[3-[[7-Propyl-3-phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]piperidin-2,6-
dione **652993-15-2P**, 4-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-
benzisoxazol-6-yl]oxy]propyl]morpholine-3,5-dione **652993-17-4P**,
1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-
yl]oxy]propyl]piperazine-2,5-dione **652993-20-9P**,
3-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-
1,3,5-triazinane-2,4-dione **652993-22-1P**, 3-[3-[[7-Propyl-3-
phenyl-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione

652993-23-2P, 6-Methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]dihydropyrimidine-2,4(1H,3H)-dione **652993-24-3P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]azepan-2-one **652993-25-4P**, 1-Phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidine-2,4-dione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)

RN 652992-23-9 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-24-0 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-25-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-26-2 CAPLUS
CN 2,5-Pyrrolidinedione, 3,3-dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-27-3 CAPLUS
CN 2,5-Pyrrolidinedione, 3-methyl-3-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-28-4 CAPLUS
CN 2,4-Thiazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-29-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-30-8 CAPLUS
CN 2,4-Thiazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-5,5-dimethyl- (9CI) (CA INDEX NAME)



RN 652992-31-9 CAPLUS
CN 5-Thiazolidineacetic acid, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 652992-33-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-34-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-35-3 CAPLUS
CN 2,4-Imidazolidinedione, 1-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-36-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652992-37-5 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-38-6 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 652992-41-1 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-42-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]-5-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 652992-43-3 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-44-4 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-5-phenyl-3-[4-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]butyl]- (9CI) (CA INDEX NAME)



RN 652992-45-5 CAPLUS
CN Benzoic acid, 3-[4-methyl-2,5-dioxo-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-4-imidazolidinyl]- (9CI) (CA INDEX NAME)



RN 652992-48-8 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 652992-49-9 CAPLUS
CN 2,4-Imidazolidinedione, 5-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 652992-52-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 652992-53-5 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-

benzisoxazol-6-yl]oxy]propyl]-1-pyrazinyl- (9CI) (CA INDEX NAME)



RN 652992-54-6 CAPLUS
CN 4-Imidazolidinepropanoic acid, 2,5-dioxo-4-phenyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-55-7 CAPLUS
CN 1-Imidazolidinebutanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-58-0 CAPLUS
CN 1-Imidazolidinepentanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-61-5 CAPLUS

CN 1-Imidazolidineacetic acid, α-methyl-2-oxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-62-6 CAPLUS
CN 2,4-Imidazolidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-65-9 CAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-70-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[[(1R,2S)-2-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 652992-72-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[[(1R,2S)-2-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]cyclopentyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 652992-78-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[4-[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]butyl]- (9CI) (CA INDEX NAME)



RN 652992-80-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-5-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-85-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-1,5-dimethyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-92-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-1-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652992-96-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 652993-00-5 CAPLUS
CN [1(2H),2'-Bipyrimidine]-2,4(3H)-dione, 5,6-dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-04-9 CAPLUS
CN [1(2H),5'-Bipyrimidine]-2,4(3H)-dione, 5,6-dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-06-1 CAPLUS
CN 2-Piperidinone, 1-[3-[[3-(2,2-dimethylpropyl)-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-08-3 CAPLUS
CN 2-Piperidinone, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-10-7 CAPLUS
CN 2,6-Piperidinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-13-0 CAPLUS
CN 2,6-Piperidinedione, 1-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-15-2 CAPLUS
CN 3,5-Morpholinedione, 4-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-17-4 CAPLUS
CN 2,5-Piperazinedione, 1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-20-9 CAPLUS
CN 1,3,5-Triazine-2,4(1H,3H)-dione, dihydro-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-22-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-3-[3-[(3-phenyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-23-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, dihydro-6-methyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-24-3 CAPLUS
CN 2H-Azepin-2-one, hexahydro-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 652993-25-4 CAPLUS
CN 2,4-Imidazolidinedione, 1-phenyl-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



IT **652992-57-9P**, Ethyl 4-[5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]imidazolidin-1-yl]butanoate **652992-64-8P**, 1-[3-[[7-Propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-3-(4-methoxybenzyl)imidazolidine-2,4-dione
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of benzisoxazoles as LXR ligands for treating dyslipidemic conditions)

RN 652992-57-9 CAPLUS

CN 1-Imidazolidinebutanoic acid, 5,5-dimethyl-2,4-dioxo-3-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 652992-64-8 CAPLUS

CN 2,4-Imidazolidinedione, 3-[(4-methoxyphenyl)methyl]-1-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:314695 CAPLUS Full-text
DN 132:334473
TI Preparation of (carbamoylmethyl)pyrazinones as thrombin inhibitors
IN Sanderson, Philip E.; Lyle, Terry A.; Dorsey, Bruce D.; Stanton, Matthew G.; Staas, Donnette; Coburn, Craig; Naylor-Olsen, Adel M.; Morrissette, Matthew M.; Selnick, Harold G.; Nanterment, Philippe G.; Williams, Peter D.; Stauffer, Kenneth J.; Burgey, Christopher; Isaacs, Richard
PA Merck & Co., Inc., USA; Barrow, James, C.
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000026211	A1	20000511	WO 1999-US25203	19991028
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2348734	AA	20000511	CA 1999-2348734	19991028
	EP 1124822	A1	20010822	EP 1999-958684	19991028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 747776	B2	20020523	AU 2000-15997	19991028
	JP 2002528543	T2	20020903	JP 2000-579599	19991028
	US 6610692	B1	20030826	US 1999-429741	19991028
PRAI	US 1998-106417P	P	19981030		
	WO 1999-US25203	W	19991028		

OS MARPAT 132:334473
GI


I


II

AB The (carbamoylmethyl)pyrazinones I [wherein b = NY1 or O; c = CY2 or N; d = CY3 or N; e-g = CY4 or N; Y1 and Y2 = independently H, (cyclo)alkyl, halogen, NH2, OH, or alkoxy; Y3 = H, (cyclo)alkyl, halogen, CN, NH2, or alkoxy; Y4 = independently H, alkyl, or halogen; W = H, R1, R1O2C, R1CO, R1SO2, R1(CH2)nNHCO, or (R1)2CH(CH2)nNHCO; n = 0-4; R1 = H, (un)substituted (cycloalkyl)alkyl, alkoxyalkyl, difluoroalkyl, carboxyalkyl, Ph, naphthyl, heterocyclyl, etc.; X = H or halogen; R3 = H, (cyclo)alkyl, halogen, (un)substituted Ph, acyl, heterocyclyl, CN, SMe, SOMe, or alkylsulfonyl] and its analogs were prepared I inhibited human α-thrombin and are expected to be useful as blood platelet aggregation inhibitors, thrombus formation

inhibitors, anticoagulants, and thrombolytics. Thus, 3-(2-phenylethylamino)-6-methyl-1- carboxymethylpyrazinone was amidated by 5-aminomethylindole in DMF in the presence of HOBT, EDC, and TEA to yield the (indolylmethylcarbamoylmethyl) pyrazinone II, which showed thrombin inhibitory activity with a Ki of ≤ 20 nM.

IT **267874-82-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (heterocyclylmethylcarbamoylmethyl)pyrazinones as thrombin inhibitors)

RN 267874-82-8 CAPLUS

CN 1(2H)-Pyrazineacetamide, 6-methyl-N-[(3-methyl-1,2-benzisoxazol-5-yl)methyl]-2-oxo-3-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:614472 CAPLUS Full-text
DN 111:214472
TI Preparation of 3-piperidinyl-1,2-benzisoxazoles as psychotic drugs
IN Antoku, Fujio; Yoshigi, Mayumi; Saji, Ikutaro; Ishizumi, Kikuo
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 314098	A2	19890503	EP 1988-117836	19881026
	EP 314098	A3	19900103		
	EP 314098	B1	19930804		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01199967	A2	19890811	JP 1988-266754	19881021
	CA 1335289	A1	19950418	CA 1988-581028	19881024
	US 4937249	A	19900626	US 1988-262575	19881025
	AT 92489	E	19930815	AT 1988-117836	19881026
	ES 2059468	T3	19941116	ES 1988-117836	19881026
PRAI	JP 1987-271462	A	19871026		
	EP 1988-117836	A	19881026		

OS MARPAT 111:214472
GI



AB The title compds. (I; A = CO, SO2; when A = CO, B = Q1-Q5; when A = SO2, B = 1,2-phenylene; R1 = R2 = H; or either one of R1, R2 = H, the other = OH, C1-5 alkyl, C2-6 alkanoyloxy; R1R2 = O; E = O, CH2, CH2CH2; F = CH2, CH2CH2; R3-R8 = H, C1-5 alkyl; R9-R12 = C1-5 alkyl; R11R12 = C3-5 alkylene; n = 0-2; W = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-6 hydroxyalkylene; G = H, C1-5 alkyl, C1-5 alkoxy, halo, HO) were prepared as psychotic drugs useful as highly selective neuroleptics, active also as analgesics, allergy inhibitors,and cardiovascular agents. A mixture of N-(4-bromobutyl)cyclohexane-1,2-dicarboximide, 3-(4-piperidinyl)-6- fluoro-1,2-benzisoxazole, K2CO3, and KI in DMF was heated 11 h at 90-100°to give 72.8% N-[4-[4-(6-fluoro-1,2-benzisoxazol-3- yl)piperidinyl]butyl]cyclohexane-1,2-dicarboximide (II). In a test for neuroleptic activity against pos. symptoms, II suppressed the climbing behavior in mice induced by apomorphine with an ED50 of 0.92 mg/kg after 1 h, vs. 1.8 and 9.4 mg/kg for chlorpromazine and tiaspirone, resp.

IT **123547-84-2P 123547-85-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antipsychotic)

RN 123547-84-2 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperidinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 123547-85-3 CAPLUS

CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(6-methyl-1,2-benzisoxazol-3-yl)-1-piperidinyl]butyl]-, monohydrochloride, (3aα,4β,7β,7aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d l2; d l7; d his; log y
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

L7 HAS NO ANSWERS
L6 STR



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.
L7 QUE ABB=ON PLU=ON L6

(FILE 'HOME' ENTERED AT 09:59:44 ON 10 NOV 2005)

FILE 'REGISTRY' ENTERED AT 09:59:53 ON 10 NOV 2005
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 2 S L2
L4 76 S L2 FUL

FILE 'CAPLUS' ENTERED AT 10:00:16 ON 10 NOV 2005
L5 12 S L4
FILE 'REGISTRY' ENTERED AT 10:00:23 ON 10 NOV 2005
L6 STRUCTURE UPLOADED
L7 QUE L6
L8 2 S L7 SAM SUB=L4
L9 63 S L7 FUL SUB=L4
FILE 'CAPLUS' ENTERED AT 10:01:37 ON 10 NOV 2005
L10 4 S L9

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.21	221.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

STN INTERNATIONAL LOGOFF AT 10:02:26 ON 10 NOV 2005